Considering the diuretic actions of BMT (Younus and Reddy, 2018) and its hearing impairment at high dose (Allegaert et al., 2016), the new BMT-derivative drugs such as STS66 may be more effective in blocking brain NKCC1 protein activity with less side effects. Here, SLC12A2 is linked to Hearing impairment.